Effects of 3-4 diaminopyridine (DAP) in XXXX .

@entity1 @entity425 @entity4681 @entity63404 @entity746
OBJECTIVE: To study the safety of 3-4 @entity63404 (DAP) in @entity1 with @entity4681 and to examine its efficacy in reducing muscle fatigue and @entity425 and in improving objective parameters of muscle function. DESIGN: Assessments of safety included a questionnaire of symptoms, clinical examination, blood testing, and electrocardiography at each visit; efficacy was assessed by subjective scores of fatigue and @entity425 ; an Amyotrophic Lateral Sclerosis Functional Rating Scale and functional ability scores, including timed verbal scores; manual muscle testing; grip dynamometry; pulmonary function tests; timed functional tests; and electrophysiological studies. @entity1 : Thirteen subjects with @entity746 and seven subjects with only a lower motor neuron syndrome. MAIN OUTCOMES: Assess tolerability of DAP and determine if there was symptomatic improvement of muscle fatigue. SECONDARY OUTCOME: To determine the effects of DAP on objective parameters of muscle function. RESULTS: The drug was well tolerated with only four subjects reporting tingling of lips and fingers during the active drug period. The subjective scores for fatigue and @entity425 showed a mild improvement after 4 weeks on DAP compared with placebo. A significant benefit of DAP was also demonstrated in the timed verbal scores. CONCLUSION: 3-4 DAP appeared to be safe and produced subjective benefit in @entity4681 . The drug could be added for symptomatic treatment in these diseases. Larger studies are necessary to demonstrate efficacy.
